Cycurion wins $800K in new annual contracts
Cycurion outlines about $800,000 in new annual contract work as it advances its commercial healthcare, life sciences, and public-health strategy alongside its government franchise.
Rhea-AI Filing Summary
Cycurion, Inc. (CYCU) reported that it has secured several new commercial and public-health engagements totaling approximately $800,000 in annual contract spend. These include a pharmaceutical-industry engagement to support an AI Center of Excellence, a new award from the National Association of County and City Health Officials (NACCHO), and additional commercial and public-health work.
The company states that these awards represent progress on its strategy to expand in commercial healthcare, life sciences, and other non-government sectors while continuing to serve its government and public-safety customers. Work under these contracts covers business continuity and disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and AI operating capability.
Positive
- None.
Negative
- None.
Filing Explained
As of September 3, commercial engagements were announced, but their timing, performance, and benefits remained unresolved in the filing.
The
As a Form 8-K Item 8.01 filing, it reports an other event and furnishes the press release as Exhibit 99.1 rather than presenting a separate financial statement or transaction closing.
The release expressly treats the engagements’ scope, timing, duration, performance, and anticipated benefits as forward-looking, and identifies contract modifications, delays, or terminations as risks.
Later 10-Qs or 8-Ks are the relevant places to watch for changed contract status or evidence of execution; the release says subsequent events may change the company’s plans and expectations.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Annual contract spend from new engagements: $800,000
1 metrics
Annual contract spend from new engagements
$800,000
Aggregate annual contract spend associated with new awards announced September 3, 2026
Key Terms
annual contract spend, AI Center of Excellence, business continuity and disaster recovery, organizational change management, +1 more
5 terms
annual contract spend financial
"engagements totaling approximately $800,000 in annual contract spend"
AI Center of Excellence technical
"a pharmaceutical-industry engagement to support an AI Center of Excellence"
A AI center of excellence is an internal team or hub that develops, governs and scales an organization’s artificial intelligence projects, acting like a central workshop that sets standards, shares tools and trains staff. For investors, it matters because a well-run center can speed innovation, reduce costly mistakes, improve efficiency and ensure consistent results across products and operations, while a weak one can mean wasted spending, slow execution or higher operational risk.
business continuity and disaster recovery technical
"Scope across the engagements includes business continuity and disaster recovery"
organizational change management technical
"Scope across the engagements includes ... organizational change management"
Organizational change management is the structured process companies use to plan, communicate, and guide people through major shifts in strategy, systems, processes, or culture. It matters to investors because effective change management helps ensure projects meet timelines and budgets, preserves employee productivity and customer relationships during transitions, and reduces the risk that planned benefits or cost savings fail to materialize; think of it as managing a household renovation while keeping the house livable.
forward-looking statements regulatory
"This press release contains forward-looking statements as defined"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What new contract value did Cycurion (CYCU) announce in this 8-K?
Cycurion announced approximately $800,000 in annual contract spend from several new engagements. These include a pharmaceutical AI Center of Excellence, a NACCHO award, and additional commercial and public-health work, all supporting its commercial expansion strategy.
Which sectors are covered by Cycurion’s new $800,000 in annual contracts?
The new contracts span pharmaceutical, healthcare, and public health sectors. They include a pharmaceutical AI Center of Excellence engagement, a new NACCHO award, and other commercial and public-health work, aligning with Cycurion’s push into non-government markets.
How does the $800,000 in contracts fit Cycurion (CYCU)’s strategy?
The company states the approximately $800,000 in annual contract spend helps convert its stated commercial strategy into work in pharmaceutical, healthcare, and public health, while it continues to operate its government and public-safety franchise.
What services will Cycurion provide under the newly announced engagements?
Across the new contracts, Cycurion will provide business continuity and disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and support for an AI Center of Excellence for a pharmaceutical organization.
What relationship does Cycurion have with NACCHO under these new awards?
Cycurion reports a new NACCHO award included in the approximately $800,000 annual contract spend. The award deepens its existing relationship with NACCHO, where Cycurion already holds the status of a Diamond Affiliate Partner.
Does Cycurion plan further commercial expansion beyond these new contracts?
Yes. Cycurion states it will continue to seek additional commercial and non-government opportunities that match its capabilities in cybersecurity, managed IT, program delivery, and AI-enabled transformation, while maintaining government and public safety as core markets.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 3, 2026
(Exact Name of Registrant as Specified in Its Charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (888 ) 341-6680
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events.
On September 3, 2026, the Company issued a press release. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits:
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated September 3, 2026 | |||||||
| 104 | Inline XBRL for the cover page of this Current Report on Form 8-K | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CYCURION, INC. | ||||||||||||||
| Date: | September 8, 2026 | By: | /s/ L. Kevin Kelly | |||||||||||
| Name: | L. Kevin Kelly | |||||||||||||
| Title: | Chief Executive Officer | |||||||||||||
3
Exhibit 99.1
Cycurion Announces Approximately $800,000 in Annual Contract Spend, Accelerating Commercial Expansion
September 3, 2026
First public announcement of a pharmaceutical AI Center of Excellence engagement, a NACCHO award, and additional commercial and public-health work
MCLEAN, Va., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity and AI-driven solutions, today announced several engagements totaling approximately $800,000 in annual contract spend. The work includes a pharmaceutical-industry engagement to support an AI Center of Excellence, a new award with the National Association of County and City Health Officials (NACCHO), and additional commercial and public-health engagements. This is the first public announcement of these awards.
This is the commercial expansion Cycurion told the market it was going after. The Company is building commercial healthcare and life-sciences work as a primary growth market, while continuing to run its government and public-safety franchise. Scope across the engagements includes business continuity and disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and AI operating capability.
The announcement reflects the Company’s deliberate strategy — as previously communicated to the market — to accelerate expansion into commercial healthcare, life sciences, and other non-government sectors where demand for resilient IT, cybersecurity, and AI-enabled operating capability continues to grow.
“These wins are exactly the kind of commercial traction we told the market we were going after,” said L. Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. “A pharmaceutical organization has engaged us to support its AI Center of Excellence. NACCHO has awarded new work. Customers are not paying for slogans. They are paying for resilience, cybersecurity, program delivery, and AI that has to run in a real operating environment. Each of these engagements puts us inside an organization that will need more of what we do. We are not dabbling in commercial. We are building it.”
What the Work Covers
Across the commercial and NACCHO-related engagements, Cycurion is supporting clients with:
•Business continuity and disaster recovery planning and execution
•Technology and cybersecurity assessments
•Program management for complex technology initiatives
•Organizational change management
•Support for an AI Center of Excellence for a pharmaceutical organization
The pharmaceutical AI Center of Excellence engagement is a commercial life-sciences win the Company has been building toward. The NACCHO award is being announced for the first time and deepens Cycurion’s existing relationship with the association, including its standing as a Diamond Affiliate Partner. Additional commercial and public-health work is included in the approximately $800,000 annual contract-spend total.
Why It Matters
The number is approximately $800,000 in annual contract spend. The signal is the market. These engagements convert a stated commercial strategy into work in pharmaceutical, healthcare, and public health, and they put Cycurion inside accounts that can grow. Government and public safety remain core. Commercial is a market Cycurion is going after.
The Company will continue to pursue additional commercial and non-government opportunities that fit its capabilities in cybersecurity, managed IT, program delivery, and AI-enabled transformation.
About Cycurion, Inc.
Based in McLean, Virginia, Cycurion (Nasdaq: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. For more information, visit www.cycurion.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, statements regarding the approximately $800,000 in aggregate annual contract spend associated with the new awards; the scope, timing and duration of the services to be provided under those awards; the Company’s ability to perform under the new contracts and to realize their anticipated benefits; the development of an AI Center of Excellence for a pharmaceutical organization; the expansion of the Company’s commercial healthcare, life sciences and other non-government business; the Company’s expectation that these engagements will lead to additional work with these clients; the deepening of the Company’s relationship with NACCHO and its member organizations; the Company’s ability to identify and win additional commercial and non-government opportunities; the continued execution on the Company’s backlog; and other statements that are not historical facts. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, risks related to customer performance and satisfaction, contract modifications, delays or terminations, and the Company’s ability to fulfill contractual obligations; the outcomes of the Company’s investigations, any potential legal proceedings, or the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.
2
Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com
Cycurion Media Relations:
(888) 341-6680
media@cycurion.com
3